| Bioactivity | Brodalumab (AMG 827) is a human anti-interleukin-17-receptor IgG2 monoclonal antibody that can be used for the research of moderate-to-severe plaque psoriasis and rheumatoid arthritis[1][2]. |
| Target | IL-17R |
| Invitro | Brodalumab (AMG 827) 通过 IL-17RA/RC 复合物阻断 IL-17A、IL-17F 和 IL17-A/F 异源二聚体信号通路的生物活性，以及通过 IL-17RA/RB 复合物阻断 IL-25 (IL-17E) 信号通路的生物活性[2]。Brodalumab 能够抑制银屑病的炎症过程[2]。 |
| Name | Brodalumab |
| CAS | 1174395-19-7 |
| Appearance | Liquid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Papp KA, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012 Mar 29;366(13):1181-9. [2]. Martin DA, et al. A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis. Arthritis Res Ther. 2013 Oct 25;15(5):R164. |